Latest News

Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021

As of June 30, 2021, cash and cash equivalents were EUR 36.9 million (USD 43.9 million) which includes EUR 13.5 million from the third and final tranche of IPF loan triggered by the recent approval of the…

Read this Press Release: Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021

Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements

Following the recent approval of TWYMEEG® (Imeglimin) in Japan and associated potential future revenues, Poxel to accelerate and expand rare metabolic disease programs leveraging existing platforms and…

Read this Press Release: Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements

Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021

Pr. Kenneth Cusi presented the results of the STAMP-NAFLD 12-week, randomized, controlled Phase 2a trial of PXL770 in 120 presumed NASH patients – selected as a “Best of ILC” abstract Pr. Vlad Ratziu…

Read this Press Release: Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

Targeting Mitochondrial Dysfunction

Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and will be marketed by our strategic partner, Sumitomo Dainippon Pharma, in 2021. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership